- Molecular NameProbucol
- Synonym4,4'- (Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2, 6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis(2,6-di-tert-butylphenol); 4,4'-(Isopropylidenedithio)bis[2, 6-di-tert-butylphenol]; Acetone bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis (3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Acetone, bis(3,5-di-tert-butyl-4-hydroxyphenyl) mercaptole; Probucolum [inn-latin]
- Weight516.855
- Drugbank_IDDB01599
- ACS_NO23288-49-5
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)10.58
- pkaN/A
- LogD (pH=7, predicted)10.58
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-8.16
- LogSw (predicted, AB/LogsW2.0)0.0
- Sw (mg/ml) (predicted, ACD/Labs)0.0
- No.of HBond Donors2
- No.of HBond Acceptors2
- No.of Rotatable Bonds8
- TPSA91.06
- StatusFDA approved
- AdministrationN/A
- PharmacologyAn anti-hyperlipidemic drug initially developed in the treatment of coronary artery disease. However, clinical trials were stopped after it was found that it causes long QT syndrome in patients.
- Absorption_value7.0
- Absorption (description)Absorption from the gastrointestinal tract is limited and variable (about 7%).
- Caco_2N/A
- Bioavailability5.0
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmN/A
- Half lifeRanges from 12 hours to more than 500 hours, the longest half-life probably being in adipose tissue.
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityBepridil can cause dose-related prolongation of the QT interval.
- LD50 (rat)N/A
- LD50 (mouse)LD50>5000